1st Quarter - Termination
SUMITOMO PHARMA AMERICA, INC.(FORMERLY SUNOVION PHARMACEUTICALS INC.) for SUMITOMO PHARMA AMERICA, INC. (FORMERLY SUNOVION PHARMACEUTICALS INC.)
Income
—
Expenses
$210,000
Expense method
A: Lobbying Disclosure Act definitions
Terminated
Mar 15, 2024
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Inflation Reduction Act Medicare Part D 6 Protected Classes H.R.5237, The Reduced Cost and Continued Cures Act SMART Prices Act (S. 1264) Lowering Drug Costs for American Families Act (H.R. 4895) Executive Order on Strengthening Access to Affordable, High Quality Contraception & Family Planning Services Accelerating Kids Access to Care Act (S. 2372, H.R. 4758) The Modernizing and Ensuring PBM Accountability Act (no bill # yet) Medicaid Drug Rebate Proposed Rule
| Lobbyist | Covered position, as disclosed |
|---|---|
| THERESA JOLIVETTE | — |
| ERIC RASMUSSEN | — |
| BELA SASTRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.